Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ: BJDX) is a late-stage, pre-revenue diagnostics and medical device company headquartered in Acton, Massachusetts, developing the Symphony platform for near-patient critical-care testing. Its lead product, the Symphony IL-6 rapid diagnostic test, is designed to assess 28-day mortality risk in sepsis patients at the bedside. On August 5, 2026, the company announced that its pivotal SYMON-II multicenter clinical validation study — a 750-patient sepsis cohort — completed enrollment ahead of schedule, a milestone the stock (+24.00% that day) treated as a key step toward regulatory submission and commercialization.